Good news for psoriasis patients. The National Health Insurance proposes to extend the benefits for biologic products

26 March, 2015

Subject: Amendment to payment policy for drugs containing etanercept

According to: Article 41 of the National Health Insurance Act and The National Health Insurance Pharmaceutical Benefits and Reimbursement Schedule.

Announcement: Amendment to section 8.2.4.6 regarding the use of immunologic agents etanercept (e.g. Enbrel), adalimumab (e.g. Humira), and ustekinumab (e.g. Stelara) in psoriasis treatment under Section 8, Article 83 in Chapter 6 of The National Health Insurance Pharmaceutical Benefits and Reimbursement Schedule. Please see attachment for the comparison table of amendments to benefits (please retrieve the file online from http://www.nhi.gov.tw by clicking “announcement” in the homepage).